SABCS   |  December 12, 2019   Trastuzumab Deruxtecan Shows Promise in Heavily Pretreated Patients With HER2+ BC T-DXd demonstrated improved and durable response rates in heavily pretreated patients with advanced HER2-positive breast cancer. Read more   ADVERTISEMENT   Addition of Pertuzumab to Previous Standards Improves IDFS in HER2+ Breast Cancer The addition of pertuzumab to the previous standard of trastuzumab plus chemotherapy as an adjuvant therapy for patients with operable HER2-positive early breast cancer continued to reduce the risk for recurrence and death during a 6-year updated analysis. Read more